Genomictree Inc.
228760
Clasificación en acciones
#19173
Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to... Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to develop and market advanced detection tools for both oncological conditions and various infectious diseases. Its product line includes EarlyTect C, a screening solution for the early identification of colorectal cancer. For lung cancer, it offers EarlyTect L, which targets epigenetic markers in patients with pulmonary nodules, and for bladder cancer, EarlyTect B, designed to detect specific genetic and epigenetic markers in individuals with hematuria. The company also provides a range of companion diagnostics: AccuraTect-KRAS and AccuraTect-BRAF assist in colorectal cancer management, while AccuraTect-EGFR supports lung cancer treatment. In addition, Genomictree supplies AccuraDTect SARS-CoV-2 RT-qPCR kits for infectious disease testing, and offers its technologies to support various diagnostic test providers. Founded in 2000, the company is based in Daejeon, South Korea.
Precio por acción
$6.61
Capitalización bursátil
$162.26M
Cambio (1 día)
1.06%
Cambio (1 año)
-50.87%
País
KR
Comercio Genomictree Inc. (228760)
Categoría
Healthcare
Capitalización de mercado de Genomictree Inc.(228760)
Capitalización bursátil: $162.26M
A fecha de October 2026, Genomictree Inc. tiene una capitalización de mercado de $162.26M. Esto convierte a Genomictree Inc. en la 19173rd empresa más valiosa del mundo por capitalización bursátil, según nuestros datos. La capitalización bursátil es el valor total de mercado de las acciones en circulación de una empresa que cotiza en bolsa y se utiliza comúnmente para medir su valor.
Historial de capitalización de mercado de Genomictree Inc. desde 2017 hasta 2026
228760 en comparación con los más populares 5 títulos stocks
